Literature DB >> 18222509

Thalassaemia screening in a non-prevalent region of a prevalent country (Turkey): is it necessary?

H Acemoglu1, N E Beyhun, S Vancelik, H Polat, A Guraksin.   

Abstract

OBJECTIVES: Haemoglobinopathies are the most widespread inherited disorders in the world, and are also common in Turkey. Haemoglobinopathies are preventable with control programmes. Therefore, the Ministry of Health initiated a control and prevention programme in 33 provinces in Turkey. The aim of this study was to determine the frequency of haemoglobinopathies in Erzurum as part of the programme mentioned above, and to discuss the need for premarital screening in a non-prevalent region (Erzurum) of a prevalent country (Turkey) as part of a national control programme. STUDY
DESIGN: Epidemiological and descriptive survey.
METHODS: This study was conducted between May 2005 and February 2006 in Erzurum. Subjects were couples who attended for premarital screening. All blood samples were measured by high-performance liquid chromatography (HPLC) to determine haemoglobinopathies.
RESULTS: In total, 1610 individuals were screened. The frequency of beta-thalassaemia trait was 0.68%. Haemoglobin D was the most common (0.12%) abnormal haemoglobin. Haemoglobins S, C and E were not detected. The frequency of beta-thalassaemia trait and other haemoglobinopathies in Erzurum was quite low compared with other provinces in Turkey.
CONCLUSIONS: Premarital haemoglobinopathy screening should not be mandatory in a non-prevalent region of a prevalent country as part of a national control programme. If screening is mandatory, it should be performed by total blood count or enzyme-linked immunosorbent assay, which are simple, rapid and less expensive than HPLC.

Entities:  

Mesh:

Year:  2008        PMID: 18222509     DOI: 10.1016/j.puhe.2007.09.007

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  5 in total

Review 1.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

2.  Molecular spectrum of α-globin gene mutations in the Aegean region of Turkey: first observation of three α-globin gene mutations in the Turkish population.

Authors:  Hüseyin Onay; Ayça Aykut; Emin Karaca; Asude Durmaz; Aslı Ece Solmaz; Özgür Çoğulu; Yeşim Aydınok; Canan Vergin; Ferda Özkınay
Journal:  Int J Hematol       Date:  2015-05-05       Impact factor: 2.490

3.  β-Globin chain abnormalities with coexisting α-thalassemia mutations.

Authors:  Birol Guvenc; Abdullah Canataroglu; Cagatay Unsal; Sule Menziletoglu Yildiz; Ferda Tekin Turhan; Sevcan Tug Bozdogan; Suleyman Dincer; Hakan Erkman
Journal:  Arch Med Sci       Date:  2012-05-29       Impact factor: 3.318

4.  First Observation of Hb South Florida [beta 1(NA1) Val>Met] in Turkey.

Authors:  Ayça Dilruba Aslanger; Aynur Akbulut; Gül Tokgöz; Sakine Türkmen; Kanay Yararbaş
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

5.  β-Thalassemia mutations and hemoglobinopathies in Adana, Turkey: results from a single center study.

Authors:  Birol Guvenc; Abdullah Canataroglu; Cagatay Unsal; Sule Menziletoglu Yildiz; Ferda Tekin Turhan; Sevcan Tug Bozdogan; Suleyman Dincer; Hakan Erkman
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.